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Stratification of cumulative antibiograms in hospitals for hospital
unit, specimen type, isolate sequence and duration of hospital
stay
Abstract
Background Empirical antibiotic therapy is based on patients' characteristics and antimicrobial
susceptibility data. Hospital-wide cumulative antibiograms may not sufficiently support informed
decision-making for optimal treatment of hospitalized patients. Methods We studied different
approaches to analysing antimicrobial susceptibility rates (SRs) of all diagnostic bacterial isolates
collected from patients hospitalized between July 2005 and June 2007 at the University Hospital in
Zurich, Switzerland. We compared stratification for unit-specific, specimen type-specific (blood,
urinary, respiratory versus all specimens) and isolate sequence-specific (first, follow-up versus all
isolates) data with hospital-wide cumulative antibiograms, and studied changes of mean SR during the
course of hospitalization. Results A total of 16 281 isolates (7965 first, 1201 follow-up and 7115 repeat
isolates) were tested. We found relevant differences in SRs across different hospital departments. Mean
SRs of Escherichia coli to ciprofloxacin ranged between 64.5% and 95.1% in various departments, and
mean SRs of Pseudomonas aeruginosa to imipenem and meropenem ranged from 54.2% to 100% and
80.4% to 100%, respectively. Compared with hospital cumulative antibiograms, lower SRs were
observed in intensive care unit specimens, follow-up isolates and isolates causing nosocomial infections
(except for Staphylococcus aureus). Decreasing SRs were observed in first isolates of
coagulase-negative staphylococci with increasing interval between hospital admission and specimen
collection. Isolates from different anatomical sites showed variations in SRs. Conclusions We
recommend the reporting of unit-specific rather than hospital-wide cumulative antibiograms. Decreasing
antimicrobial susceptibility during hospitalization and variations in SRs in isolates from different
anatomical sites should be taken into account when selecting empirical antibiotic treatment.
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ABSTRACT (250 words) 27 
Background: Empirical antibiotic therapy is based on patients' characteristics and 28 
antimicrobial susceptibility data. Hospital-wide cumulative antibiograms may not 29 
sufficiently support informed decision making for optimal treatment of hospitalized 30 
patients. 31 
Methods: We studied different approaches in analyzing antimicrobial susceptibility 32 
rates (SR) of all diagnostic bacterial isolates collected from patients hospitalized 33 
between July 2005 and June 2007 at the University Hospital in Zurich, Switzerland. 34 
We compared stratification for unit-specific; specimen type-specific (blood, urinary, 35 
respiratory versus all specimens); and isolate sequence-specific (first, follow-up 36 
versus all isolates) data with hospital-wide cumulative antibiograms; and studied 37 
changes of mean SR during the course of hospitalization. 38 
Results: A total of 16,281 isolates (7,965 first, 1,201 follow-up and 7,115 repeat 39 
isolates) were tested. We found relevant differences in SR across different hospital 40 
departments. Mean SR of Escherichia coli to ciprofloxacin ranged between 64.5 and 41 
95.1% in various departments, and mean SR of Pseudomonas aeruginosa to 42 
imipenem and meropenem ranged from 54.2 to 100% and 80.4 to 100%, 43 
respectively. Compared with hospital cumulative antibiograms, lower SR were 44 
observed in intensive care unit specimens, follow-up isolates and isolates causing 45 
nosocomial infections (except for Staphylococcus aureus). Decreasing SR were 46 
observed in first isolates of coagulase-negative staphylococci with increasing interval 47 
between hospital admission and specimen collection. Isolates from different anatomic 48 
sites showed variations in SR. 49 
Conclusions: We recommend to report unit-specific rather than hospital-wide 50 
cumulative antibiograms. Decreasing antimicrobial susceptibility during 51 
   
hospitalization and variations in susceptibility rates in isolates from different anatomic 52 
sites should be taken into account when selecting empirical antibiotic treatment. 53 
   
INTRODUCTION 54 
Antibiotic resistance rates vary widely between countries,1-3 within countries,4 and 55 
between as well as within health care institutions.5 The worldwide emergence of 56 
antibiotic resistance due to increased and inappropriate antibiotic use reduces 57 
treatment options and the overall efficacy of antimicrobials.2, 6 In patients with 58 
presumed acute infection, initial empirical antibiotic therapy - before results of 59 
pathogen identification and susceptibility testing are available - is selected based on 60 
individual patient's characteristics, clinical differential diagnosis, place of infection 61 
(i.e., community versus hospital-acquired), and non-patient-related epidemiological 62 
data such as local bacterial susceptibility rates.5, 7 The choice of empirical 63 
antibacterial therapy in hospitalized patients is guided by institution-specific 64 
cumulative antibiogram reports, which compile mean susceptibility rates of bacterial 65 
isolates collected from other patients previously treated at the same institution. 66 
Guidelines for the analysis and preparation of cumulative antibiograms in hospitals 67 
have recently been updated.8 They recommend to only include the first isolate per 68 
episode of a patient's infection in order to reduce potential overestimation of 69 
antimicrobial resistance due to multiple specimens from the same patient. However, 70 
it may not be adequate to base empirical antibiotic therapy for individual patients on 71 
hospital-wide overall susceptibility rates.5 Incorrect initial empirical treatment may 72 
affect outcome, particularly in critically ill patients.9, 10 73 
In order to support guidelines for empirical antibiotic therapy at our institution, we 74 
aimed to compare the hospital-wide cumulative antibiograms of inpatients with the 75 
results of additional subanalyses of susceptibility data. In particular, we stratified 76 
hospital unit-specific versus hospital-wide susceptibility rates; anatomic site-specific 77 
(blood, urinary, respiratory versus all specimens); isolate sequence-specific (first, 78 
   
follow-up versus all isolates); and hospitalization phase-specific (considering the time 79 
between admission and specimen collection) susceptibility data. 80 
   
MATERIALS AND METHODS 81 
Setting 82 
The University Hospital in Zurich, Switzerland, is an 860 beds tertiary care 83 
teaching hospital. It covers all medical specialties except for paediatrics and 84 
orthopaedics. Six intensive care units (medical ICU, general, thoracic and transplant 85 
surgery ICU, trauma ICU, burn ICU, cardiac surgery ICU, neurosurgery ICU) with a 86 
total of 59 beds are assigned to different departments. Bone marrow transplantations 87 
are performed in a specialized unit. 88 
 89 
Data collection 90 
Antimicrobial susceptibility rates were assessed and recorded during routine 91 
clinical patient care for all diagnostic bacterial isolates obtained from inpatients 92 
hospitalized in intensive care units and general wards between July 1, 2005 and 93 
June 30, 2007, and were analyzed retrospectively. For comparisons of nosocomial 94 
and community-acquired isolates, isolates from patients spending >24 hours in the 95 
emergency unit, its observation ward or surgical observation wards were also 96 
included. Screening isolates (e.g. samples that were analyzed at our Hospital 97 
Epidemiology Department in order to asses the need for ongoing isolation measures 98 
in patients who had previously been identified as carriers of methicillin-resistant 99 
Staphylococcus aureus and Extended-Spectrum Beta-Lactamase producing 100 
Enterobacteriaceae) were excluded. All specimens were tested in a central clinical 101 
microbiology laboratory (Institute of Medical Microbiology, University of Zurich, 102 
Zurich, Switzerland). Bacteria were isolated from blood cultures and other materials 103 
according to standard methods.11 Susceptibility testing of bacterial isolates was 104 
performed by the disk diffusion method; zone diameters were interpreted according 105 
   
to the NCCLS (CLSI) guidelines.11 Intermediate susceptibility was categorized as 106 
non-susceptible.  107 
The isolates were categorized by the patient's unit of hospitalization at the time of 108 
specimen collection; the anatomic site of specimen recovery (blood culture, urinary, 109 
respiratory or other); and the year of collection. Unless specified otherwise, 110 
susceptibility rates of first isolates are reported according to the recently published 111 
Clinical Laboratory Standards Institute (CLSI) guidelines.8 The problem of handling 112 
different phenotypes with different resistance patterns of an isolate has not been 113 
addressed in these guidelines. Hence, we counted one organism if an isolate 114 
revealed two or more phenotypes of the same organism. However, we included all 115 
phenotypes if they showed different resistance patterns. As a result, the number of 116 
susceptibility testing results exceeds the total number of organisms. Recovery of a 117 
minimum of 30 isolates per each hospital unit or anatomic site of infection was 118 
required to be included in the analysis, as recommended.8 119 
Among the repeat isolates, we analyzed the first follow-up isolates in two groups, 120 
which were a priori defined, i.e., ‘early’ follow-up isolates collected between day 0 121 
and 2 after the first isolate, and ‘late’ follow-up isolates collected more than 2 and 122 
equal or less than 10 days after the first isolate. 123 
Nosocomial isolates were defined as isolates that were collected more than 48 124 
hours after hospital admission and less than 30 days after discharge (in case of 125 
readmission) or, in case of missing date of specimen collection, if they arrived at the 126 
Institute of Medical Microbiology more than 72 hours after hospital admission.  127 
Respiratory isolates were defined as isolates recovered from tracheal aspirates, 128 
bronchial aspirates or broncho-alveolar lavage. No assessments against other 129 
confounders were made when analyzing data on pathogen susceptibility from 130 
different anatomic locations. 131 
   
Antimicrobial susceptibility rates of all bacterial isolates were determined, but we 132 
limit our report to the analyses of Escherichia coli, Pseudomonas aeruginosa, 133 
Staphylococcus aureus and coagulase-negative staphylococci, as these organisms 134 
were isolated most frequently, accounting for 28% of all first isolates. 135 
 136 
Statistical analyses 137 
We used Stata (Version 9.2, StataCorp, College Station, Texas) for statistical 138 
analyses. Fisher's exact test was used in the analysis of categorical data. Exact 95% 139 
confidence intervals for binomial variables were calculated. No adjustments for 140 
multiple testing were made. A two-tailed p value of less than 0.05 was considered to 141 
be statistically significant. 142 
 143 
   
RESULTS 144 
A total of 16,281 diagnostic bacterial isolates from hospitalized patients were 145 
tested during the 2-year study period. Among these, 7,965 were first, 1,201 were 146 
follow-up isolates (according to our definition) and 7,115 were other repeat isolates.  147 
 148 
Unit-specific versus hospital-wide cumulative antibiograms 149 
Table 1 displays the range of hospital-unit-specific susceptibility rates, i.e. the 150 
mean rates of the unit with the lowest and the unit with the highest susceptibility rate, 151 
in comparison with the mean hospital-wide cumulative susceptibility rate of first 152 
isolates of E. coli, P. aeruginosa, S. aureus and coagulase-negative staphylococci. 153 
Figure 1 depicts mean susceptibility rates of E. coli in each single ICU and ward. 154 
We detected significant differences in the overall susceptibility rates of E. coli and 155 
P. aeruginosa between departments, i.e., for E. coli tested against ampicillin, 156 
amoxicillin/clavulanic acid, piperacillin/tazobactam, ciprofloxacin and 157 
trimethoprim/sulfamethoxazole; for P. aeruginosa tested against ceftriaxone, 158 
imipenem, meropenem, piperacillin/tazobactam and tetracycline; and for coagulase-159 
negative staphylococci tested against ampicillin, oxacillin, aminoglycosides, 160 
trimethoprim/sulfamethoxazole, ciprofloxacin, erythromycin, clindamycin and 161 
rifampicin. For S. aureus isolates, significant differences across departments were 162 
only detected for penicillin resistance rates. 163 
The most striking and clinically relevant variations in susceptibility rates between 164 
departments were: 165 
- mean E. coli susceptibility rate to amoxicillin/clavulanic acid, ranging from 62.5 166 
(thoracic and transplant surgery ICU) to 92.7% (department of neurosurgery); 167 
- mean E. coli susceptibility rate to ciprofloxacin, ranging from 64.5 (department 168 
of dermatology) to 95.1% (department of neurosurgery); 169 
   
- mean E. coli susceptibility rate to trimethoprim/sulfmethoxazole, ranging from 170 
58.1 (department of rheumatology) to 86.1% (department of neurology); 171 
- mean P. aeruginosa susceptibility rate to piperacillin/tazobactam, ranging from 172 
85.0 (medical ICU) to 100% (departments of dermatology and gynecology and 173 
obstetrics); 174 
- mean P. aeruginosa susceptibility rate to imipenem and meropenem, ranging 175 
from 54.2 (thoracic and transplant surgery ICU) to 100% (department of 176 
gynecology and obstetrics) and from 80.4 (thoracic and transplant surgery 177 
ICU) to 100% (department of gynecology and obstetrics), respectively; and 178 
- mean P. aeruginosa susceptibility rate to ciprofloxacin, ranging from 80.0 179 
(medical ICU) to 95.2% (trauma ICU). 180 
 181 
ICUs versus general wards 182 
Figure 2 contrasts the susceptibility rates of first isolates of E. coli and P. 183 
aeruginosa recovered from intensive care units (E. coli, n=333, P. aeruginosa, 184 
n=290) and general wards (E. coli, n=993, P. aeruginosa, n=277). The proportion of 185 
isolates of P. aeruginosa susceptible to imipenem (SR, 67.97% and 90.14%, 186 
respectively, p<0.001) and meropenem (SR, 89.56% and 95.67%, respectively, 187 
p=0.004) was significantly lower in ICUs than in general wards. In contrast, general 188 
wards had significantly higher rates of ciprofloxacin-resistant E. coli than ICUs (SR, 189 
81.64% and 90.39%, respectively, p<0.001). 190 
 191 
First versus follow-up versus all isolates 192 
Figure 3 compares the cumulative antibiograms of first versus follow-up isolates 193 
obtained between days 0-2 and 3-10 after the first isolate, respectively, versus all 194 
isolates of E. coli and P. aeruginosa. 195 
   
First isolates of E. coli (n=1,326) and P. aeruginosa (n=567) were significantly 196 
more susceptible to various antibiotics than follow-up isolates (E.coli, n=221 (‘early’ 197 
follow-up isolates) and n=180 (‘late’ follow-up isolates), respectively; P. aeruginosa, 198 
n=163 (‘early’ follow-up isolates) and n=165 (‘late’ follow-up isolates), respectively) or 199 
all isolates (E. coli, n=2,491, P. aeruginosa, n=1,768). Except for the susceptibility 200 
rate of E.coli tested to ampicillin (SR, 30.98% (‘late’ follow-up isolates) and 40.97% 201 
(all isolates), respectively, p=0.013), no significant differences in susceptibility rates 202 
were detected between ‘late’ follow-up and all isolates. 203 
 204 
Community-acquired versus nosocomial isolates 205 
Differences between community-acquired and nosocomial isolates are shown in 206 
table 2. Community-acquired isolates of E. coli, P. aeruginosa and of coagulase-207 
negative staphylococci were significantly more often susceptible against various 208 
antibiotics than nosocomial isolates. No significant differences between nosocomial 209 
and community-acquired isolates regarding antibiotic susceptibility were observed 210 
with S. aureus. 211 
 212 
Changes of cumulative antibiograms during the course of hospitalization 213 
We considered the interval between hospital admission and the collection of a first 214 
specimen and calculated cumulative antibiograms of these first isolates for different 215 
phases of hospital stay (Figure 4). A sustained and significant decrease in 216 
susceptibility rates during the course of hospitalization could be observed in 217 
coagulase-negative staphylococci tested against gentamicin, oxacillin and rifampicin, 218 
but not in E. coli tested against ciprofloxacin, ceftriaxone, amoxicillin/clavulanic acid 219 
or piperacillin/tazobactam. Data on changes of susceptibility rates of P. aeruginosa 220 
   
could not be completely obtained due to low numbers of first isolates in some of the 221 
time periods that were assessed. 222 
 223 
Blood, urine or respiratory tract isolates versus all first isolates 224 
We found significant differences in susceptibility rates of organisms recovered 225 
from different anatomic sites (Figure 5). For example, respiratory isolates of E.coli 226 
(n=114) were significantly more often susceptible to ciprofloxacin than first E.coli 227 
isolates overall (n=1,768) (SR, 92.11% and 83.83%, respectively, p<0.001). The 228 
susceptibility rate to trimethoprim/sulfamethoxazole of E.coli isolates recovered from 229 
blood cultures (n=94) was significantly lower than the respective overall susceptibility 230 
rate (SR, 50.00% and 70.20%, respectively, p<0.001). Furthermore, the proportion of 231 
urinary isolates of P. aeruginosa (n=107) with susceptibility to imipenem (SR, 88.89% 232 
and 78.62%, respectively, p=0.012), meropenem (SR, 98.02% and 92.51%, 233 
respectively, p=0.049) and ceftazidime (SR, 99.05% and 93.40%, respectively, 234 
p=0.020) was higher than the corresponding susceptibility rate of all isolates (n=567), 235 
whereas isolates from respiratory specimens (n=190) were more often resistant to 236 
imipenem (SR, 64.10% and 78.62%, respectively, p<0.001). 237 
   
DISCUSSION 238 
Information from cumulative antibiogram reports is an important basis for the 239 
selection of empirical antibacterial therapy. Using stratified analyses of the bacterial 240 
susceptibility test results at our hospital, we found clinically highly relevant 241 
dissimilarities of susceptibility rates of important bacterial pathogens across various 242 
hospital departments, and between intensive care units and general wards. 243 
Furthermore, follow-up isolates (identified between more than 48 hours and 10 days 244 
after the first isolate) of a variety of bacterial species were less susceptible than first 245 
isolates. Likewise, increased duration between hospital admission and specimen 246 
collection was associated with reduced antimicrobial susceptibility rates of some 247 
bacterial species. Finally, isolates from different anatomic sites differed in their 248 
susceptibility rates. 249 
Susceptibility rates of bacterial isolates from certain departments may differ from 250 
those of a hospital overall, as previously shown 5, but comprehensive data on unit-251 
specific data are scarce in the literature. We found striking differences of cumulative 252 
antibiograms across different departments of our hospital. For example, mean 253 
susceptibility rates of Escherichia coli to ciprofloxacin ranged between 64.5 and 254 
95.1%; and those of Pseudomonas aeruginosa to imipenem and meropenem ranged 255 
from 54.2 to 100% and 80.4 to 100%, respectively. Furthermore, the results of our 256 
study are in agreement with findings of previous studies reporting differences in the 257 
prevalence of antimicrobial resistance among various pathogens between intensive 258 
care units (ICUs), non-ICU units, overall hospital data, and between different ICUs of 259 
a single institution 5, 12-14. 260 
Calculations of cumulative antibiograms based on all isolates tend to overestimate 261 
resistance rates due to repeat collection of strains from patients with complicated 262 
clinical course, long hospital stay, or with nosocomial infections.15-17 Also, specimen-263 
   
collection practices, i.e. the frequency of repeat cultures during patients' evaluation or 264 
the use of surveillance cultures in ICUs, may influence susceptibility rates. Therefore, 265 
guidelines to prepare cumulative antibiogram reports recommend to exclude repeat 266 
isolates per episode, and emphasize that the "first isolate per patient approach" had 267 
direct relevance to guiding selection of initial empirical therapy. In contrast, the 268 
likelihood of the emergence of antimicrobial resistance during prolonged or repeat 269 
therapy has to be taken into account during management of prolonged or re-270 
occurring infections. 271 
There is no consensus on the definition of a new infectious episode following a 272 
first one in an individual patient, and there are no recommended calculation 273 
algorithms to detect such consecutive infectious episodes by analyzing 274 
microbiological laboratory data sets.8 However, the "first isolate approach" may 275 
underestimate the resistance rate of complicated infections because first isolates are 276 
often collected early in the course of a disease. Therefore, the knowledge of the 277 
resistance rates of follow-up isolates may help to empirically adjust antibiotic therapy 278 
in patients whose clinical condition is deteriorating despite presumably adequate 279 
initial antibiotic coverage. In order to explore susceptibility data in complicated 280 
infections, we investigated a definition for ‘late’ follow-up isolates (i.e., isolate 281 
identification between more than 48 hours and 10 days after the first one) which is 282 
expected to exclude most duplicate isolates. We found that, in general, mean 283 
susceptibility rates of ‘late’ follow-up isolates were lower than first isolates at our 284 
institution. However, we also observed that resistance rates of ‘late’ follow-up isolates 285 
were similar to the mean of all isolates. Consequently, the easily computable "all 286 
isolate approach" may reflect the resistance pattern of more complicated infection 287 
and may serve as an important information in addition to the first isolate 288 
antibiograms. 289 
   
Isolates from nosocomial infections are generally regarded less susceptible to 290 
antibiotics than community-acquired organisms, but this is not true for all bacteria or 291 
for all hospital sites and geographic areas.18-20 Nosocomial infection is usually 292 
considered if it begins more than 48 h after hospital admission. Nonetheless, the 293 
point in time during the course of a hospitalization that best discriminates between 294 
more susceptible and more resistant pathogens remains unclear. To our knowledge, 295 
there are no data available regarding the influence of the time between hospital 296 
admission and specimen collection on cumulative antibiograms. The effects of 297 
antibiotic use on resistance rates in hospitals have been described previously.21, 22 298 
We observed that mean susceptibility rates of coagulase-negative staphylococci for 299 
gentamicin, oxacillin and rifampicin continuously and significantly decreased in the 300 
course of hospitalization, reflecting the overall selection pressure of antibiotic use in 301 
an institution. In contrast, no significant or sustained decrease of susceptibility was 302 
detected for E. coli, P. aeruginosa and S. aureus. Of note, the rate of methicillin-303 
resistant S. aureus (MRSA) at our institution and in the surrounding region is with 304 
approx. 3% exceptionally low. However, as no typing work was done, it remains 305 
unclear whether modifications of the primary pathogen or hospital acquisition of 306 
different strains have a greater influence on these results. Nevertheless, these 307 
findings indicate that a duration of hospitalization of more than 48 h before diagnosis 308 
of infection and initiation of empirical antibacterial therapy may not by itself be a 309 
sufficient criterion for the use of broad-spectrum antibiotic or MRSA-covering 310 
substances. 311 
Whether the anatomic site of specimen collection should be accounted for in 312 
cumulative antibiograms is unclear. Analyses comparing resistance rates in isolates 313 
from different body sites or blood revealed conflicting results, and only few data on 314 
systematic evaluations are available.5, 23, 24 We found variations in susceptibility rates 315 
   
between specimens of different sources, but these differences were small for most 316 
drug-organism combinations. Nevertheless, we observed some significant 317 
discrepancies such as increased carbapenem resistance in many respiratory P. 318 
aeruginosa isolates, or an increased resistance rate in uropathogens. 319 
Limitations of the calculation of cumulative antibiograms have been recognized 5. 320 
Because laboratory data sets are based on the resistance profiles of all isolates sent 321 
to the microbiology laboratory, infection and colonization cannot be distinguished. A 322 
patient's localization in the hospital at the time of sample collection may not represent 323 
the site where infection was acquired. Furthermore, even though screening samples 324 
for surveillance purposes are usually marked, some screening isolates might have 325 
been included in our analyses. We cannot exclude that we found some differences 326 
which could be chance findings due to multiple testing. 327 
In conclusion, we found significant and clinically relevant discrepancies of mean 328 
antimicrobial susceptibility patterns at our institution depending on the strategy used 329 
for data analyses of cumulative antibiograms. From a practical standpoint, data 330 
reporting including multiple stratification may not appear feasible at present, but the 331 
knowledge of variations of susceptibility rates, specifically within an institution, during 332 
different phases of hospitalization, or of infections at different anatomic sites, may 333 
particularly be beneficial for empirical antibiotic therapy of complicated infections. In 334 
the future, electronic decision support systems may integrate the results of stratified 335 
cumulative antibiograms. We recommend the reporting of unit-specific cumulative 336 
antibiograms, although prospective studies are needed to evaluate the impact of 337 
such reporting on antibiotic use, treatment outcome and costs. Furthermore, teaching 338 
antibiotic policies and visualization of the antibiotic selection pressure within the own 339 
institution may be supported by depicting institution-specific data of selected 340 
   
examples of frequent bacterial isolates with decreasing susceptibility rates during the 341 
course of hospitalization.  342 
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Table 1: Hospital-wide antibiograms and range of unit-specific susceptibility 433 
rates of the departments with the lowest and the highest rates. 434 
 Mean susceptibility rates (% of isolates) 
 
Escherichia coli 
(n=1,326) 
Pseudomonas aeruginosa 
(n=567) 
 hospital-wide lowest highest 
hospital-
wide lowest highest 
Ampicillin 52.2 40.0 69.4 0.0 0 0 
Amoxicillin/clavulanic acid 82.6 62.5 92.7 0.5 0.0 3.3 
Piperacillin/tazobactam 97.3 87.5 100 94.6 85.0 100 
First-generation cephalosporin 78.5 71.7 96.8 0.2 0.0 1.4 
Cefuroxime 90.3 83.7 95.8 1.0 0.0 4.1 
Ceftriaxone 97.4 94.1 100 11.8 0.0 22.7 
Ceftazidime 97.0 92.5 100 93.4 89.7 100 
Cefepime 97.5 97.0 100 92.9 87.2 96.2 
Imipenem 100.0 100 100 78.6 54.2 100 
Meropenem 100.0 100 100 92.5 80.4 100 
Tobramycin 93.4 85.7 98.4 95.8 92.6 100 
Trimethoprim/sulfamethoxazole 70.2 58.1 86.1 3.7 0.0 11.1 
Ciprofloxacin 83.8 64.5 95.1 88.5 80.0 95.2 
Tetracycline 66.2 61.6 82.1 5.5 0.0 16.7 
  
 
Staphylococcus aureus 
 
(n=1,231) 
Coagulase-negative 
staphylococci 
(n=1,430) 
Amoxicillin/clavulanic acid 96.3 92.9 100    
Ampicillin 24.0 20.5 31.0 15.7 0.0 24.0 
Oxacillin 96.3 92.9 100 41.0 12.8 60.0 
Amikacin 99.3 97.5 100 86.9 53.1 98.6 
Gentamicin 98.4 96.2 100 67.3 12.8 73.1 
Tobramycin 96.7 94.5 100 56.5 8.3 77.1 
Trimethoprim/sulfamethoxazole 98.9 97.0 100 58.0 10.6 76.0 
Ciprofloxacin 93.1 87.5 100 48.4 8.7 93.1 
Erythromycin 92.3 88.6 95.1 41.3 17.0 57.6 
Clindamycin 98.2 95.8 100 65.7 53.1 96.6 
Rifampicin 99.6 97.4 100 84.5 72.9 96.9 
Vancomycin/Teicoplanin 100 100 100 99.3 97.3 100 
   
Table 2: Differences in susceptibility rates of community-acquired and nosocomial isolates. 435 
 
Mean susceptibility rates (% of isolates) [95% confidence interval] 
 
Escherichia coli Pseudomonas aeruginosa 
 community-acquired (n=729) 
nosocomial  
(n=1,017) P-value 
community-acquired 
(n=219) 
nosocomial 
(n=485) P-value 
Ampicillin 55.70 [52.05-59.31] 48.47 [45.40-51.55] 0.003 0.45 [0.01-2.51] 0.21 [0.00-1.14] 0.527 
Amoxicillin/clavulanic acid 85.85 [83.12-88.29] 80.60 [78.05-82.97] 0.004 1.36 [0.28-3.93] 0.61 [0.13-1.79] 0.381 
Piperacillin/tazobactam 98.50 [97.33-99.25] 96.50 [95.18-97.54] 0.010 96.36 [92.96-98.42] 94.18 [91.74-96.07] 0.273 
First-generation cephalosporin 82.38 [79.44-85.07] 76.24 [73.52-78.81] 0.002 0.00 [0.00-1.67] 0.41 [0.05-1.47] 1.000 
Cefuroxime 92.94 [89.68-95.42] 89.04 [86.01-91.16] 0.071 1.66 [0.34-4.77] 1.63 [0.39-1.97] 1.000 
Ceftriaxone 97.94 [96.63-98.84] 97.16 [95.94-98.09] 0.354 10.76 [7.02-15.59] 12.05 [9.32-15.24] 0.707 
Ceftazidime 97.60 [96.24-98.57] 96.58 [95.30-97.59] 0.262 94.12 [90.15-96.83] 93.00 [90.40-95.08] 0.631 
Cefepime 98.83 [97.04-99.68] 96.72 [94.81-98.08] 0.069 94.05 [89.61-96.99] 93.24 [90.49-95.40] 0.860 
Imipenem 100.00 [99.50-100.00] 100.00 [99.64-100.00]  87.95 [82.95-91.90] 76.65 [72.69-80.28] <0.001 
Meropenem 100.00 [99.49-100.00] 100.00 [99.94-100.00]  94.09 [90.11-96.82] 92.17 [89.45-94.37] 0.436 
Tobramycin 95.10 [93.27-96.54] 91.80 [89.94-93.40] 0.007 94.14 [90.19-96.85] 95.93 [93.78-97.49] 0.336 
Trimethoprim/sulfamethoxazole 69.65 [66.19-72.95] 67.22 [64.26-70.08] 0.006 6.36 [3.52-10.45] 3.87 [2.35-5.98] 0.176 
Ciprofloxacin 94.38 [81.55-86.92] 83.27 [80.84-85.51] 0.566 87.00 [81.86-91.11] 88.17 [85.03-90.85] 0.713 
 
Staphylococcus aureus Coagulase-negative staphylococci 
 community-acquired (n=826) 
nosocomial  
(n=836) P-value
community-acquired 
(n=372) 
nosocomial 
(n=1,261) P-value 
Amoxicillin/clavulanic acid 95.73 [94.11-97.01] 97.23 [95.88-98.24] 0.109    
Ampicillin 26.08 [23.13-29.21] 23.16 [20.35-26.16] 0.173 30.99 [26.40-35.88] 13.21 [11.42-15.17] <0.001 
Oxacillin 95. 64 [94.01-96.93] 97.25 [95.91-98.25] 0.085 73.47 [68.71-77.86] 35.70 [33.09-38.38] <0.001 
   
Gentamicin 98.91 [97.94-99.50] 98.45 [97.36-99.17] 0.521 87.53 [83.77-90.69] 63.22 [60.56-65.82] <0.001 
Trimethoprim/sulfamethoxazole 98.67 [97.62-99.33] 98.93 [97.97-99.50] 0.659 75.33 [70.66-79.60] 57.88 [55.26-60.46] <0.001 
Erythromycin 92.19 [90.10-93.96] 91.96 [89.86-93.74] 0.926 60.06 [54.62-65.32] 39.24 [36.47-42.06] <0.001 
Clindamycin 98.36 [97.22-99.13] 98.02 [96.81-98.84] 0.709 83.28 [78.85-87.12] 63.16 [60.38-65.88] <0.001 
Rifampicin 99.75 [99.09-99.97] 99.50 [98.74-99.86] 0.687 96.15 [93.51-97.94] 82.86 [80.61-84.95] <0.001 
Vancomycin/Teicoplanin 100.00 [99.55-100.00] 99.88 [99.34-100.00] 1.000 99.47 [98.09-99.94] 99.22 [98.57-99.63] 1.000 
 436 
 437 
 438 
   
FIGURE LEGENDS 439 
Figure 1 440 
Unit-specific benchmark of antibiotic susceptibility. Prevalence of susceptibility 441 
to various antibiotics among Escherichia coli recovered from different hospital sites 442 
(A-F: intensive care units, 1-8: general wards, ALL: entire hospital). Data presented 443 
as percentage of susceptible isolates ± 95% confidence interval (one-sided, 97.5 % 444 
confidence interval where susceptibility rate=100%).  445 
 446 
Figure 2 447 
Comparison of antibiotic susceptibility in intensive care units and general 448 
wards. Prevalence of susceptibility to various antibiotics among Escherichia coli and 449 
Pseudomonas aeruginosa recovered from intensive care units and general wards. 450 
Data presented as percentage of susceptible isolates ± 95% confidence interval 451 
(one-sided, 97.5 % confidence interval where susceptibility rate=100%).  452 
 453 
Figure 3 454 
Difference of antibiotic susceptibility of subsequent isolates. Prevalence of 455 
susceptibility of first, follow-up (identified >2 and ≤10 days after first isolate) and all 456 
isolates (including repeat isolates) to various antibiotics among Escherichia coli and 457 
Pseudomonas aeruginosa. Data presented as percentage of susceptible isolates ± 458 
95% confidence interval (one-sided, 97.5 % confidence interval where susceptibility 459 
rate=100%).  460 
 461 
Figure 4 462 
Change of antibiotic susceptibility during hospitalization. Changes in the 463 
susceptibility to gentamicin, rifampicin and oxacillin in the course of time after 464 
   
hospital admission among first isolates of coagulase-negative staphylococci (upper 465 
panel) and to piperacillin/tazobactam, amoxicillin/clavulanic acid (middle panel) and 466 
ceftriaxone, ciprofloxacin (lower panel) among first isolates of Escherichia coli. Data 467 
presented as percentage of susceptible isolates ± 95% confidence interval (one-468 
sided, 97.5 % confidence interval where susceptibility rate=100%). *p<0.05 469 
compared to the susceptibility rate at days 1-3. 470 
 471 
Figure 5 472 
Susceptibility of pathogens recovered from different anatomic locations. 473 
Prevalence of susceptibility to various antibiotics among Pseudomonas aeruginosa 474 
and Escherichia coli recovered from different clinical specimens. Data presented as 475 
percentage of susceptible isolates ± 95% confidence interval (one-sided, 97.5 % 476 
confidence interval where susceptibility rate = 100%).  477 
 478 
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